Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower MAP target with reduced noradrenaline in cardiogenic shock after acute myocardial infarction
NL-OMON56427Phase 4Recruiting
- Sponsor
- Cardiologs
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of norepinephrine in cardiogenic shock and myocardial infarction (MI) (2 arms), sponsored by Cardiologs. Primary endpoint: Composite of all-cause mortality and severe renal failure. Started Oct 2022; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
cardiogenic shockmyocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON56427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56427.